Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1
about
New generation humanized mice for virus research: comparative aspects and future prospectsVisualization and quantification of simian immunodeficiency virus-infected cells using non-invasive molecular imaging.Combinatorial assessments of brain tissue metabolomics and histopathology in rodent models of human immunodeficiency virus infectionLong lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis.The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages.Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.Expansion of activated memory CD4+ T cells affects infectivity of CCR5-tropic HIV-1 in humanized NOD/SCID/JAK3null mice.Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice.Cocaine-mediated impact on HIV infection in humanized BLT mice.Influence of age, irradiation and humanization on NSG mouse phenotypes.In vivo platforms for analysis of HIV persistence and eradication.Humanized Mouse Model of Ebola Virus Disease Mimics the Immune Responses in Human Disease.Full Length Single Chain Fc Protein (FLSC IgG1) as a Potent Antiviral Therapy Candidate: Implications for In Vivo Studies.HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized miceHIV therapy by a combination of broadly neutralizing antibodies in humanized mice.HIV-1 Latency and Eradication: Past, Present and FutureInfectious diseases in humanized mice.Latest animal models for anti-HIV drug discovery.ABX464: a good drug candidate instead of a magic bulletBroadly neutralizing antibodies: An approach to control HIV-1 infection.Humanized mice for HIV and AIDS research.In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies.Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice.Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice.Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice.Antibody gene transfer for HIV immunoprophylaxisRNA sequencing analysis of activated macrophages treated with the anti-HIV ABX464 in intestinal inflammation.An advanced BLT-humanized mouse model for extended HIV-1 cure studies.Functional engraftment of human peripheral T and B cells and sustained production of autoantibodies in NOD/LtSzscid/IL-2Rγ(-/-) mice.Human Immune System Mice for the Study of Human Immunodeficiency Virus-Type 1 Infection of the Central Nervous System.Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice.Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice.
P2860
Q27014786-7B1CF553-19D6-4D38-A31A-F1E3B963B2BBQ27323244-844DE649-4E94-48BA-92E0-2334A8870AB9Q28394163-3046CAB5-FE53-4D9A-A197-55ED185AB156Q30373903-7706BB5E-D2EE-4B46-91CC-DC25DF8182CDQ33884876-9F4EFB0A-1822-4858-ADE0-2E1F50E584F4Q34180174-4A02BA03-416A-411A-8CE6-361DE036568CQ34542521-BB2D08F4-A85A-4BFB-A140-53CF76729D0FQ35745432-5B2A4689-2EA4-4874-8ED8-57CC5AD25E37Q35754062-769102B0-F463-4F8E-8305-BDC7896DA98BQ36175327-CCF7715A-B598-44D7-ACF1-482685C57BEBQ36515119-841E9E90-01A5-467A-9BCB-3616D6CA6A6BQ36562881-73E1D0FB-0BBB-4FCE-A80F-420EA1DBB6D5Q36602029-0AD22C7A-D483-4992-A229-07C3C36B4392Q37236504-7D2F6BEB-DE43-4BDC-8B71-2310D20AE7D2Q37259407-9C379FD0-C90C-4BA1-902D-9F4394B51753Q37505823-0AACF3CC-9DDD-4B28-BA8C-0B6DED7861BBQ38126447-AE7EDA8C-84D1-4CC2-ADE8-B77B2253FC0EQ38263295-D138BC0E-5F99-4B6F-9CC9-83211D449A47Q38555300-08C42801-5C63-43EA-A160-8B3F1FC196D5Q38811735-A37A69D4-A982-497E-A97C-7E34A7BC7EA1Q38838864-4A5510C1-B0EF-4ABB-95C9-F8FD67E77C9BQ39315707-8E66781B-5ED2-4EF1-AA75-27741B21CB69Q40062702-C5CBCFA3-FD3C-42A9-94F7-1B7809C49E99Q40079572-AF8B75D9-5FBF-4EBC-A448-F569E21077B7Q40150911-39E73470-A655-45CA-840B-0AFF0AD8B1D0Q42060689-6C0FA871-9759-45EB-B30D-C6BEFCDA8D1EQ42379362-EE270F6E-D95E-4CC6-BAF9-4EAD504BCC76Q46813659-167B73B7-581B-46F4-AF12-576AB7E9E501Q50784754-EED87356-E8B2-4AB0-94CE-A95D7724B483Q52579149-8A9D9088-6128-44CB-AE49-D6BE88F40280Q53837345-FA7F535E-F258-47D5-8D42-4DA9B3DA4F85Q54267469-6D72EF8D-06B0-4BD3-B7B1-6002306A5032
P2860
Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Humanized mice recapitulate ke ...... viral drugs for treating HIV-1
@ast
Humanized mice recapitulate ke ...... viral drugs for treating HIV-1
@en
Humanized mice recapitulate ke ...... viral drugs for treating HIV-1
@nl
type
label
Humanized mice recapitulate ke ...... viral drugs for treating HIV-1
@ast
Humanized mice recapitulate ke ...... viral drugs for treating HIV-1
@en
Humanized mice recapitulate ke ...... viral drugs for treating HIV-1
@nl
prefLabel
Humanized mice recapitulate ke ...... viral drugs for treating HIV-1
@ast
Humanized mice recapitulate ke ...... viral drugs for treating HIV-1
@en
Humanized mice recapitulate ke ...... viral drugs for treating HIV-1
@nl
P2093
P2860
P1433
P1476
Humanized mice recapitulate ke ...... viral drugs for treating HIV-1
@en
P2093
Anja Van Cauwenberge
Annette Audigé
Bart Stoops
Daniel Boden
Erika Schlaepfer
Guenter Kraus
Gustavo Gers-Huber
Katie Amssoms
Marc Nischang
P2860
P304
P356
10.1371/JOURNAL.PONE.0038853
P407
P577
2012-06-13T00:00:00Z